Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Phase: PHASE3
Conditions: Fatigue in Multiple Sclerosis
Sponsor: Johns Hopkins University

1 
 
Protocol Title:  Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple 
sclerosis (TRIUMPHANT-MS) 
NCT03185065 
Date:  October 24, 2018 
 
 
 

2 
 
List of protocol modifications 
Date  
Modification 
Rationale 
7.12.2017 
• 
Added to the inclusion criteria: 
- 
Screening MFIS score cutoff was reduced from 38 
to 33 
- 
The requirement for fatigue medication washout 
was decreased from one month to two weeks 
 
• 
Added to the exclusion criteria: 
- 
Exception of marijuana and other cannabinoids  
 
• 
To help participants choose the medication that was 
most effective for them, we added to the protocol that 
“the pharmacist the study manager will unblind the 
participants after they finish all study procedures or 
when they stop participating in the trial for any reason.” 
 
• 
Added: “If the participants tolerate the study 
medications without developing any side effects, they 
will be allowed to titrate the medication according to 
the above schedule, even if they do not receive such 
instructions from the study nurse. Those participants 
who develop new or worsening symptoms, are not 
allowed to titrate the medication before receiving such 
instructions from the study nurse. 
 
• 
Added:” If physical examination and/or EDSS is 
performed by one of the neurologists in the 
participating centers (JHU or UCSF) during a clinical 
encounter in 30 days prior to the screening visit and the 
results were available for review at the time of 
screening, there is no need to repeat them and we will 
use those data during the screening. The screening labs 
will be collected if the screening visit MFIS score is >33. 
If the required labs were done in 30 days prior to 
screening and the results were available for review at 
the time of screening, there is no need to repeat the 
labs (except the urine pregnancy test).” 
 
• 
Removed from study procedures: “Positive and 
Negative Affect Schedule” 
 
• 
Added the question to the study procedures: “Going 
forward, would you choose this medication as your 
fatigue treatment?” 
 
• 
Reduced the frequency of DSMB conference calls from 
quarterly to every six months 
 
 Suggested by the study advisory 
committee  
 
 
 
 
Suggested by the study advisory 
committee 
 
Requested by the IRB 
 
 
 
 
 
Suggested by the study advisory 
committee 
 
 
 
 
 
 
 
Suggested by the study advisory 
committee 
 
 
 
 
 
 
 
 
 
 
 
Suggested by the study advisory 
committee 
 
Suggested by the study advisory 
committee 
 
 
Suggested by the study advisory 
committee 
 
8.17.2017 
• 
Changed one of Exclusion criteria: 
Requested by the DSMB 
 

3 
 
- 
Changed the “serum creatinine >2.0 at 
screening” to “GFR (glomerular filtration rate) 
< 50” 
 
• 
To increase flexibility, the washout period between 
study period changed from “a two-week washout 
period” to “a minimum of two weeks of washout” 
 
• 
Added:” For the first treatment period, if the 
participant’s eligibility is confirmed while s/he is still at 
the screening visit, the study team can randomize the 
participant and dispense the first period medication to 
the participant.” 
 
• 
We clarified the color of capsules: changed light-colored 
to “orange/red” and dark-colored to “blue”.  
 
• 
Added a window of ±3 days to the scheduled phone 
calls to participants. 
 
• 
Changed: “Participants will start taking the study 
medication of the first period of their assigned 
sequence within 60 days (instead of one month) after 
the screening visit. 
 
 
 
 
 
Suggested by the study advisory 
committee 
 
 
Suggested by the study advisory 
committee 
 
 
 
 
Clarification of the protocol 
 
 
Suggested by the study advisory 
committee 
 
Suggested by the study advisory 
committee 
 
 
3/15/2018 
• 
Added the following exclusion criteria: 
- History of long QT syndrome, atrial fibrillation or 
tachyarrythmias (other than sinus tachycardia) 
- History of ischemic or hemorrhagic stroke 
- History of glaucoma 
- History of Tourette syndrome 
 
 
• 
For contacting participants during the trial, we added 
the options of email and text messages and reduced the 
number of patient contacts to five.  
 
• 
We added the following statement regarding 
participants dropouts:” If a participant decides to stop 
the study medication or because of development of 
adverse events, is instructed by the study team to stop 
the study medication, the outcome measures of that 
particular period will be performed during the 5th week 
of that medication period (i.e. at the scheduled time 
frame). If the participant is continuing the study and is 
willing to start the study medication of the next period, 
as long as they have been off the study medication for 
at least two weeks and they have answered the 
outcome questionnaires on week 5, the medication 
period can be started immediately. If a participant 
decides to drop out of the study, stop the study 
medication and start a medication outside of the study, 
Suggested by the PI and the study 
advisory committee 
  
 
 
 
 
 
Suggested by the study advisory 
committee 
 
 
To clarify the study procedures, 
Suggested by the study advisory 
committee 
 
 
 
 
 
 
 
 
 
 
 
 

4 
 
the outcome questionnaires should be administered 
while the patient is still on the study medication or 
before they start a medication outside of the study.” 
 
• 
We added the following statement:” If physical 
examination and/or EDSS is performed by one of the 
neurologists in the participating centers (JHU or UCSF) 
during a clinical encounter in three months prior to the 
screening visit and the results were available for review 
at the time of screening, there is no need to repeat 
them.” 
 
 
 
 
Suggested by the study advisory 
committee 
 
10.24.2018 
• 
In the original protocol, we had mentioned that 50% of 
participants will be recruited at each center. To improve 
the recruitment, we changed the process:” The 
enrollment will be competitive: one center may recruit 
more participants compared to the other center.” 
Suggested by the PIs and 
discussed with the PCORI staff 
 
 
 

5 
 
Contents 
Synopsis: ....................................................................................................................................................... 8 
- History of Tourette syndrome ............................................................................................................ 9 
1. 
Introduction ........................................................................................................................................ 10 
1.1 
Background ................................................................................................................................. 10 
1.1.1. Amantadine ............................................................................................................................... 11 
1.1.2. Modafinil ................................................................................................................................... 12 
1.1.3. Psychostimulants ...................................................................................................................... 12 
1.2. Comparative effectiveness studies of fatigue medications ............................................................. 12 
1.3. Rational for performing this clinical trial ......................................................................................... 13 
2. 
Study objectives .................................................................................................................................. 13 
2.1. Primary objective ............................................................................................................................. 13 
2.2. Secondary objectives ....................................................................................................................... 13 
3. 
Investigational plan ............................................................................................................................. 14 
3.1. Study design ..................................................................................................................................... 14 
3.2. Rationale of study design ................................................................................................................. 16 
3.3. Rationale of dose/regimen and duration of treatment ................................................................... 16 
4. 
Population ........................................................................................................................................... 17 
4.1. Inclusion criteria:.............................................................................................................................. 17 
4.2. Exclusion criteria: ............................................................................................................................. 18 
4.3. Pre-specified participant subgroups ................................................................................................ 18 
5. 
Treatment ........................................................................................................................................... 19 
5.1. Investigational treatments ............................................................................................................... 19 
5.1.1. Amantadine: .............................................................................................................................. 19 
5.1.2. Modafinil: .................................................................................................................................. 19 
5.1.3. Methylphenidate: ..................................................................................................................... 20 
5.2. Treatment arms ............................................................................................................................... 20 
5.3. Treatment assignment ..................................................................................................................... 21 
5.4. Treatment blinding .......................................................................................................................... 21 
5.5. Treating the patient ......................................................................................................................... 21 
5.5.1. Patient numbering .................................................................................................................... 21 
5.5.2. Dispensing the study treatments .............................................................................................. 21 
5.5.3. Supply, storage and tracking of the study treatments ............................................................. 22 

6 
 
5.5.4. Instructions for prescribing and taking study treatments ........................................................ 22 
5.5.5. Concomitant treatment ............................................................................................................ 23 
5.5.6. Discontinuation of study treatments and premature patient withdrawal ............................... 23 
5.5.7. Study completion ...................................................................................................................... 24 
5.5.8. Role of site personnel ............................................................................................................... 24 
Recruitment, visit schedule and assessments (Table 2) ............................................................................. 26 
6.1. Information to be collected on screening failures ........................................................................... 28 
6.2. Patient demographics and other baseline characteristics ............................................................... 29 
6.3. Efficacy ............................................................................................................................................. 29 
6.3.1. MFIS .......................................................................................................................................... 29 
6.3.2. Neuro-QOL fatigue item bank ................................................................................................... 29 
6.3.3. Epworth Sleepiness Scale (ESS) ................................................................................................. 30 
6.3.4. Single question regarding treatment satisfaction .................................................................... 30 
6.4. Safety and tolerability ...................................................................................................................... 30 
7. Safety monitoring.................................................................................................................................... 30 
7.1. Adverse events ................................................................................................................................. 30 
7.2. Pregnancies ...................................................................................................................................... 31 
7.4. Data and Safety Monitoring Board (DSMB) ..................................................................................... 31 
8.Database management ............................................................................................................................ 31 
8.1. Data collection ................................................................................................................................. 31 
8.2. Database management and quality control .................................................................................... 32 
9. Data analysis ........................................................................................................................................... 32 
9.1. Analysis sets ..................................................................................................................................... 32 
9.2. Patient demographics and other baseline characteristics ............................................................... 32 
9.3. Analysis of the primary and secondary outcomes ........................................................................... 33 
9.3.1. Primary and secondary efficacy outcomes ............................................................................... 33 
9.3.2. Statistical model, hypothesis and method of analysis .............................................................. 33 
9.3.3. Handling of missing values and discontinuations ..................................................................... 34 
9.4. Safety and tolerability outcomes ..................................................................................................... 35 
9.5. Assessment of heterogeneity of treatment effect .......................................................................... 35 
9.6. Sample size calculation .................................................................................................................... 36 
9.7. Interim analyses ............................................................................................................................... 37 
10. Ethical considerations ........................................................................................................................... 37 

7 
 
10.1. Regulatory and ethical compliance ................................................................................................ 37 
10.2. Informed consent procedures ....................................................................................................... 38 
10.4. Publication of the study protocol and results ................................................................................ 38 
11. Protocol adherence ............................................................................................................................... 38 
12. References ............................................................................................................................................ 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

8 
 
Synopsis: 
Protocol title: Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple 
sclerosis (TRIUMPHANT-MS) 
Indication: Fatigue in multiple sclerosis (MS) 
Objectives 
To compare the efficacy of commonly used fatigue medications in patients with multiple 
sclerosis.  
Trial design: Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind 
(participants and investigators), multicenter trial of 3 commonly used medications for treatment 
of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued 
subjects with MS defined by McDonald Criteria. 
Number of patients: 136 
Target population: Adult patients with MS and fatigue. 
Inclusion criteria: 
- Age 18 years and older.  
- Females of childbearing age must have a negative urine pregnancy test at baseline and 
use an effective method of contraception during the study. 
- Diagnosis of MS (according to the 2010 McDonald criteria). 
- Expanded Disability Status Scale (EDSS) score at the time of screening 0.0-7.0.  
- Fatigue reportedly present and screening Modified Fatigue Impact Scale (MFIS) score 
more than 33.  
- At least a two-week washout for any fatigue-related drug, including study medications.  
Exclusion criteria: 
- Neurodegenerative disorders other than relapsing or progressive MS.  
- Breastfeeding or pregnant.  
- History of coronary artery disease or congestive heart failure.  
- Uncontrolled hypertension at screening (history of high blood pressure and screening 
systolic blood pressure >160 or diastolic blood pressure>100).  
- GFR (glomerular filtration rate) < 50.  
- Abnormal liver function at screening (AST or ALT more than twice the upper limit of 
normal). 

9 
 
- Terminal medical conditions. 
- Currently treated for active malignancy. 
- Planned surgery or move within 8 months of screening. 
- Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).  
- A history of intolerance or allergic or anaphylactic reaction to amantadine, modafinil, 
methylphenidate or any component of the preparation. 
- Clinically unstable medical or psychiatric disorders that require acute treatment as 
determined by the PI. 
- Concurrent use of monoamine oxidase inhibitors-B.  
- Hypersensitivity/idiosyncrasy to sympathomimetic amines 
- Inability to communicate or answer the questionnaires in English or Spanish. 
- Severe untreated anemia (blood hemoglobin <9gr/dl) 
- History of untreated hypothyroidism  
- History of untreated sleep apnea  
- History of long QT syndrome, atrial fibrillation or tachyarrythmias (other than sinus 
tachycardia) 
- History of ischemic or hemorrhagic stroke 
- History of glaucoma 
- History of Tourette syndrome 
 
Study duration:  Study participation period includes screening period and treatment period.  
- Screening period duration is one months.  
- Treatment period is 6 weeks for each study drug. 
Investigational products: Participants will receive amantadine, modafinil, methylphenidate and 
placebo in a randomly assigned sequence (Figure 1 on page 13). Each medication will be titrated 
over four weeks to the participants’ highest tolerated dose or the pre-defined highest dose. The 
dosing and titration schedule of the study medications are depicted in Figure 2 on page 13:  
 
Assessments: 
Efficacy: Questionnaires- Modified fatigue impact scale (MFIS), NeuroQOL fatigue item bank 

10 
 
Safety: Safety blood tests, urine pregnancy test, adverse event collection, concomitant 
medication review 
The primary efficacy outcome is the MFIS score at the end of each treatment period. The 
secondary efficacy outcome is the average Neuro-QoL fatigue item bank score at the end of each 
treatment period. 
Study locations: This study will be conducted at the University of California San Francisco (UCSF) 
and Johns Hopkins University (JHU).  
 
Sample size and statistical analysis 
With an intraclass correlation coefficient (ICC) of 0.7, power of 90% and type one error of 0.05 
(Bonferroni corrected for 6 pairwise comparisons), we will need 91 patients to detect at least a 
10-point difference in MFIS between the placebo and medication groups. Assuming 20% dropout 
within each treatment period, the total sample size for the proposed trial will be 136 subjects. 
We will use a linear mixed-effect regression model for the primary outcome measure of the study 
(MFIS  total score) while taking maximal tolerated or target dose in each treatment period as the 
independent variable, and the study medication, treatment sequences, treatment periods and 
study sites as the fixed effects with the subjects as the random effect. If this test is significant at 
the 0.05 level, we will make pairwise comparisons between study treatments using estimated 
contrast at 0.05 level.  The secondary efficacy outcome will be analyzed using a similar mixed-
effect model. 
The safety outcome will be analyzed by including all subjects who have received at least one dose 
of study medication. Participants will be analyzed according to the actual treatment received. 
The assessment of safety will be based on the frequency of adverse events. Tolerability of 
medications will be reported as the range, median and average highest tolerated dose for each 
medication.   
Data Collection Method 
We will use Redcap (http://project-redcap.org/), a secure web application for building online 
databases, as the trial data management software. It is housed at UCSF. Most of the trial data, 
including screening and baseline values of MFIS and questionnaires answered in each study 
period will be directly captured via REDCap forms by the participants. If a participant cannot enter 
data online, (s)he will complete a paper form and mail it to the study coordinator who will 
perform data entry. Alternatively, the study coordinator will call the subject who will answer 
questions on the phone, and data will be entered at that time by the study coordinator. 
1. Introduction 
1.1 Background  
Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of the 
central nervous system (CNS) which is the most common cause of non-traumatic disability in 

11 
 
young adults (Frohman et al., 2006).  MS usually presents with focal neurological deficit affecting 
motor function, sensation, balance, vision and bladder and bowel function. Additional symptoms 
such as fatigue can also contribute greatly to disability. Fatigue, defined by a subjective lack of 
physical or mental energy perceived by the individual with usual activities, is in fact the most 
common and one of the most disabling MS symptoms as it affects at least 75 percent of patients 
at some point (Krupp, 2006, Janardhan and Bakshi, 2002; Lerdal et al., 2007). Although fatigue is 
commonly seen in many chronic conditions (particularly inflammatory diseases and cancers), it 
may have distinct characteristics in MS. Fatigue limits patients’ daily activities and 
communications (Blaney and Lowe-Strong, 2009) and results in loss of work hours and 
employment, with substantial socioeconomic consequences (Smith and Arnett, 2005). Some 
have suggested that fatigue might impact patients’ quality of life as much as ambulatory issues 
(Foley and Brandes, 2009). However, research to elucidate its pathophysiology has not been very 
fruitful (Induruwa et al., 2012).  The multiple factors that can contribute to fatigue in MS further 
complicates the picture. Primary fatigue is thought to be mainly due to immunological 
derangement and CNS damage; however, several other conditions that are commonly seen in 
patients with MS, such as sleep problems related to legs spasms, urinary changes, and depression 
can add to the burden of fatigue and can be difficult to distinguish from primary fatigue (Braley 
and Chervin, 2010).   
Despite its prevalence and social impact, fatigue treatments have been inconsistently studied 
(Toosy et al., 2014) in part due to the above-mentioned complexity of quantification as well as 
difficulty to discriminate primary fatigue from other contributing factors. Yet to be defined 
biological processes and lack of clear treatment targets have also hampered the development of 
drugs for fatigue. As a result, there are no medications approved by the Food and Drug 
Administration (FDA) for the treatment of MS fatigue.  Although several agents have been tested 
for fatigue, methodological limitations in the design, execution and reporting of those trials have 
not allowed meta-analyses or systematic reviews to conclude about efficacy. Instead systematic 
reviews have recommended performing rigorously designed trials to confirm drug effect (Pucci 
et al., 2007; Tejani et al., 2012). Moreover, the rare head-to-head clinical trials comparing 
different medications have been small and provided inconsistent results (Ledinek et al., 2013; 
Shaygannejad et al., 2012; Tomassini et al., 2004).  The most commonly used medications for the 
treatment of MS fatigue in clinical practice are amantadine, modafinil and methylphenidate. 
1.1.1. Amantadine 
Amantadine is an FDA-approved medication for the prophylaxis of influenza and symptomatic 
treatment of Parkinson’s disease, and is probably the most widely studied medication for MS 
fatigue. Amantadine has anticholinergic properties, changes dopamine release in the striatum 
and blocks N-methyl D-aspartate (NMDA) glutamate receptor (Yacoubian and Standaert, 2009). 
It is not clear which pharmacologic effect of amantadine may be responsible for its possible anti-
fatigue properties in MS. Despite multiple randomized controlled trials of amantadine for MS 
fatigue (Geisler et al., 1996; Krupp et al., 1995; Ledinek et al., 2013; Rosenberg and Appenzeller, 
1988; Stein et al., 1995; Tomassini et al., 2004), methodological issues and conflicting results have 

12 
 
prevented any final conclusion on effectiveness. A Cochrane systematic review concluded that 
the efficacy of amantadine in treating MS fatigue is poorly documented and emphasized the need 
for good quality randomized controlled trials (Pucci et al., 2007). 
1.1.2. Modafinil 
Modafinil is a non-amphetamine wake-promoting agent that is FDA-approved for treatment of 
narcolepsy, obstructive sleep apnea and shift work sleep disorder (Lange et al., 2009). Its 
mechanism of action is not fully elucidated; however, it is believed to increase cortical activity in 
the frontal lobes (Kumar, 2008). Three trials in MS fatigue produced inconsistent results. While 
two well-designed randomized trials reported no effects (Ledinek et al., 2013; Stankoff et al., 
2005), another non-randomized trial reported clear benefits at the lower dose (Lange et al., 
2009). A systematic review of modafinil as a treatment of fatigue in MS and several other 
neurological disorders concluded that clinical trials have provided inconsistent results (Sheng et 
al., 2013).  
1.1.3. Psychostimulants 
Psychostimulants have also been used for treatment of fatigue in various chronic conditions. The 
only randomized controlled trial of psychostimulants in MS fatigue was performed using 
pemoline, a medication used for treatment of attention deficit hyperactivity disorder (ADHD) 
(Weinshenker et al., 1992). This study concluded that pemoline may be an effective short-term 
treatment for MS fatigue, but was poorly tolerated. This medication is currently not available in 
the US. The results of trials using different doses of pemoline were also inconsistent, leaving open 
the question of the benefit of stimulants for MS fatigue (Krupp et al., 1995; Weinshenker et al., 
1992). Methylphenidate, an amphetamine-like psychostimulant approved for the treatment of 
ADHD, has been studied in several randomized controlled trials of fatigue in conditions other 
than MS (Breitbart et al., 2001; Cueva et al., 2012; Escalante et al., 2014; Kerr et al., 2012). 
Interestingly, the results of those trials have also been conflicting. Despite lack of evidence, 
methylphenidate is commonly used for the treatment of MS fatigue (Krupp and Christodoulou, 
2001). While lisdexamfetamine, another amphetamine-like stimulant, improved processing 
speed and memory in cognitively impaired MS patients, it did not affect fatigue in a phase II 
randomized controlled trial (Morrow et al., 2013). Conflicting trial results were also reported 
about anti-fatigue effects of dextroamphetamine in cancer and human immunodeficiency virus 
infection-related fatigue (Auret et al., 2009; Wagner and Rabkin, 2000). 
1.2. Comparative effectiveness studies of fatigue medications 
As reviewed above, despite the severity and pervasiveness of fatigue in MS, there is no high 
quality evidence supporting the use of any of the three commonly prescribed medications for the 
treatment of MS-related fatigue (amantadine, modafinil and methylphenidate) (RQ-1). There has 
been no head-to-head comparison of amantadine, modafinil and amphetamine-like 
psychostimulant in MS patients. A small multi-arm trial that included amantadine, modafinil and 
placebo, reported superiority of amantadine to placebo and no difference in the effect of 

13 
 
modafinil to placebo, but didn’t compare amantadine versus modafinil (Ledinek et al., 2013). 
There is a need to confirm efficacy and tolerability of drugs broadly used to treat MS fatigue. 
1.3. Rational for performing this clinical trial 
Disease-modifying treatments for MS reduce the incidence of relapses and inflammatory activity 
on magnetic resonance imaging (MRI), and may be associated with reduced long-term disability. 
In the era of broad use of disease-modifying treatments and reduced disease activity, treatment 
of residual symptoms in patients with MS has become increasingly important. Effective 
treatment of fatigue could potentially improve substantially the quality of life of patients with 
MS and their caregivers.  
As described above, some of the commonly used medications to treat MS-related fatigue have 
not been tested in randomized controlled trials (e.g. methylphenidate), trial results have been 
conflicting (e.g. modafinil) or trial design has been inadequate (e.g. amantadine). Hence, 
evidence-based recommendations cannot not be made to support the use of any agents for MS 
fatigue. 
The proposed randomized double-blind controlled trial will provide high quality evidence for or 
against the use of study medications: 1) we will have adequate power to show superiority of any 
tested agent over placebo or comparator, 2) we will have adequate allocation concealment and 
randomization, so blinding is adequate, 3) we will use a well-studied, valid and reliable 
instrument to measure MS-related fatigue, 4) and we will assess the clinical relevance of any 
treatment effect by evaluating quality of life changes during the study.  
The medications we propose to test in this study are FDA-approved for use in other conditions 
and have been used by patients with MS and other neurological condition for many years; thus, 
their side effect profile is well known. By providing evidence for superiority of one of these agents 
over the others (or lack thereof), the results of the proposed trial will be readily translated to 
clinical care. Evidence-based treatment of this very common and disabling MS symptom will 
improve patient outcomes and reduce the incidence of unwarranted adverse effects of less (or 
non-) efficacious medications.  
2. Study objectives 
2.1. Primary objective  
To determine within-subject effect of treatment with amantadine versus modafinil versus 
methylphenidate versus placebo on MS fatigue in a randomized double-blind placebo-controlled 
crossover trial. We hypothesize that use of amantadine, modafinil or methylphenidate, as 
compared to placebo, in MS, will be associated with improvement of fatigue scores over 6 weeks 
of treatment. 
2.2. Secondary objectives 
• To determine within-subject effect of treatment with amantadine versus modafinil versus 
methylphenidate versus placebo on fatigue-related quality of life in a randomized double-

14 
 
blind placebo-controlled crossover trial. We hypothesize that use of amantadine, 
modafinil or methylphenidate, as compared to placebo, will be associated with 
improvement of quality of life scores over 6 weeks of treatment. 
• To determine the safety and tolerability of treatment with amantadine versus modafinil 
versus methylphenidate versus placebo in MS fatigue. 
 
3. Investigational plan 
3.1. Study design 
This is a randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind 
(participants and investigators), multicenter trial of 3 commonly used medications for treatment 
of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued 
subjects with MS defined by McDonald Criteria.  
Using a balanced Latin-square crossover design, subjects will be allocated, in a double-blind, 
randomized fashion, to one of the four treatment sequences (Figure 1): 1) amantadine, placebo, 
modafinil, methylphenidate; 2) placebo, methylphenidate, amantadine, modafinil; 3) modafinil, 
amantadine, methylphenidate, placebo; and 4) methylphenidate, modafinil, placebo and 
amantadine. Each medication will be titrated over four weeks to the participants’ highest 
tolerated dose or the pre-defined highest dose. The dosing and titration schedule of the study 
medications are depicted in Figure 2.  Each treatment period will be 6 weeks and there will be a 
minimum of a 2-week washout period between each treatment period. At the beginning of the 
trial, a biostatistician at UCSF will prepare a concealed allocation schedule, randomly assigning 
the four sequences, in blocks of 4, to a consecutive series of numbers and at the time of 
enrollment, each participant will be assigned the next consecutive number (and hence the 
sequence of study medications).  
The primary endpoint of the study will be fatigue severity as measured by the MFIS score, 
between 28th and 35th day of each treatment period (while the patient is taking the maximal 
tolerated or target dose). The MFIS is a validated patient-reported outcome. The questionnaire 
will be administered remotely (through internet, phone or mailed forms) and the participants 
can answer the questions in few minutes while at home or at their work place. The questionnaire 
has been validated in English and Spanish. 
 
 

15 
 
Figure 1- Study sequences.  
Figure 2- Medication titration schedule. 
 

16 
 
3.2. Rationale of study design 
Performing a pragmatic trial with parallel-group design requires a very large sample size. Our 
proposal leverages the fact that MS-related fatigue is a chronic condition and symptomatic 
treatments used in clinic have a short half-life. A crossover design (rather than a parallel-group 
design) is the best design option that includes several advantages: 1) it will maximize efficiency 
by using each subject as his or her own control, therefore decreasing sample size and associated 
costs, and maximizing robustness (i.e. less variability of measurements with within-subject versus 
between-subjects analyses), and 2) it will likely promote recruitment as all participants will 
receive all study medications at some point during the study. The short half-life of study 
medications will allow implementing a minimum of a two-week washout period that will 
guarantee the absence of a carryover effect that could bias the results of the study.  
We will enroll a broad range of subjects with MS including relapsing and progressive forms, across 
a broad range of disability, and with or without concomitant depression or other comorbidities. 
As such, the results of the proposed trial will be highly generalizable to MS patients in general. 
To minimize the chance of harming some participants, we will exclude a small subset of patients 
who are at high risk of developing complications while receiving study medications, such as 
patients with uncontrolled hypertension or history of coronary artery disease.  
Unlike efficacy or exploratory trials in which all subjects receive a fixed dose of study medication, 
the participants in our trial will receive the highest tolerated dose of study medications (as 
opposed to a fixed target dose). Because fatigue fluctuates with the time of the day (Feys et al., 
2012), and study drugs have a relatively short half-life, we will assess fatigue severity (primary 
endpoint) in all participants at a specific time of the day (between 2-5 pm) to maximize 
consistency and minimize measurement error and variability. 
No in-person visits will be scheduled to collect the outcomes of the study after screening. Instead, 
the outcomes will be collected at participants’ home or work place through the web, phone or 
printed questionnaires. Primary and secondary trial outcomes for the proposed study are 
patient-reported, validated fatigue severity and fatigue-related quality of life measures that do 
not rely on central adjudication and can be used to assess fatigue under usual conditions.  
There will be no measurements of participant compliance in our study and analysis of primary 
and secondary outcomes will include all randomized patients regardless of their compliance.  
We took into account all the above considerations to design a clinical trial that is closer to the 
pragmatic end of the pragmatic-explanatory continuum, while maintaining the internal validity 
of the study and high power to detect a clinically significant change in the severity of fatigue and 
protect participants’ safety and well-being. 
3.3. Rationale of dose/regimen and duration of treatment 
As a pragmatic trial, comparing the effectiveness of various anti-fatigue medications, the dose of 
medications is chosen based on the most commonly used regimens by MS neurologist and 

17 
 
previous clinical trial data (if available). For example, although methylphenidate is prescribed in 
doses over 20 mg/day for treatment of various conditions, it is rare for practicing neurologists to 
prescribe doses higher than 20 mg/day for treatment of MS-related fatigue.   
The effective and tolerated dose of these medications varies among individuals. The titration 
regimen implemented in this study is trying to assess the efficacy while the participants receive 
the highest tolerated dose. This regimen will probably improve the medication compliance and 
provide more realistic information regarding the effectiveness of different medications in 
improving fatigue in MS.  
The duration of each treatment period (six weeks) was chosen based on the assumption that the 
anti-fatigue effects of these medications is not delayed and the full efficacy of these medications 
would be apparent after a few days of receiving the highest tolerated dose. Six weeks of 
treatment period would allow us to safely titrate the medications, measure the trial outcomes 
while the participants receive the highest tolerated dose, and safely taper off the medications at 
the end of the treatment period, reducing the possibility of withdrawal symptoms.  
We have considered a minimum of a two-week washout period between each treatment period, 
reducing the possibility of cross-contamination and carryover effects. The duration of the 
washout period was conservatively based on the half-life of the study medications.  
4. Population  
Adult patients (men and women aged 18 years and older) diagnosed with relapsing-remitting or 
progressive MS and reporting fatigue seen at 2 major MS centers in the US (University of 
California San Francisco (UCSF), and Johns Hopkins University (JHU)). Participants will have 
diverse racial and ethnic backgrounds, socioeconomic status, MS subtypes and disability. We are 
planning to screen 177 patients in order to enroll 136 patients in the study. The enrollment will 
be competitive: one center may recruit more participants compared to the other center, but the 
total number of enrolled participants will be 136. The study eligibility criteria were chosen to 
maximize generalizability of the results, while taking into account safety and well-being of the 
participants. 
 4.1. Inclusion criteria: 
• Age 18 years and older.  
• Females of childbearing age (potential) must have a negative urine pregnancy test at 
screening and use an effective method of contraception during the study. 
• Diagnosis of MS (according to the 2010 McDonald criteria). 
• Expanded Disability Status Scale (EDSS) score at the time of screening 0.0-7.0.  
• Fatigue reportedly present and screening Modified Fatigue Impact Scale (MFIS) score 
more than 33.  
• At least a two-week washout for any fatigue-related drug, including study medications.  
 

18 
 
4.2. Exclusion criteria: 
• Neurodegenerative disorders other than relapsing and progressive MS.  
• Breastfeeding or pregnant.  
• History of coronary artery disease or congestive heart failure.  
• Uncontrolled hypertension at screening (history of high blood pressure and screening 
systolic blood pressure >160 or diastolic blood pressure>100).  
• GFR (glomerular filtration rate) < 50 at screening.  
• Abnormal liver function at screening (AST or ALT more than twice the upper limit of 
normal). 
• Terminal medical conditions. 
• Currently treated for active malignancy. 
• Planned surgery or move within 8 months of screening. 
• Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).  
• A history of intolerance or allergic or anaphylactic reaction to amantadine, modafinil, 
methylphenidate or any component of the preparation. 
• Clinically unstable medical or psychiatric disorders that require acute treatment or as 
determined by the PI. 
• Concurrent use of monoamine oxidase inhibitors-B.  
• Hypersensitivity/idiosyncrasy to sympathomimetic amines 
• Inability to communicate or answer the questionnaires in English or Spanish. 
• Severe untreated anemia (blood hemoglobin <9gr/dl) 
• History of untreated hypothyroidism  
• History of untreated sleep apnea 
• History of long QT syndrome, atrial fibrillation or tachyarrythmias (other than sinus 
tachycardia) 
• History of ischemic or hemorrhagic stroke 
• 
History of glaucoma 
• History of Tourette syndrome 
 
4.3. Pre-specified participant subgroups 
• Relapsing-remitting versus progressive subjects. 
• Subjects who are not on disease-modifying treatments at the time of enrollment versus 
those who are. 
• Subjects with depression versus those without depression. 
• 
Subjects with mild degrees of disability (EDSS<3.0) versus those with more severe 
disability (EDSS>=3.0). 

19 
 
5. Treatment 
5.1. Investigational treatments 
As explained in the background section, amantadine, modafinil and psychostimulants are the 
most commonly used and studied medications for treatment of fatigue in MS. Although they 
have been studied and used clinically for many years, their efficacy is still unclear and there is no 
consensus among experts regarding their clinical utility. Here, we briefly review the medications 
that we have selected for the proposed study to assess their effectiveness in treatment of MS-
related fatigue: 
5.1.1. Amantadine: Amantadine is FDA-approved for the prophylaxis of influenza and 
symptomatic treatment of Parkinson’s disease. It was the first medication tried for MS-related 
fatigue (Hayden, 1996) and is probably the most widely studied medication for this indication. 
Amantadine has anticholinergic properties, changes dopamine release in the striatum and blocks 
N-methyl D-aspartate (NMDA) glutamate receptor. (Yacoubian and Standaert, 2009) It is not clear 
which pharmacologic effect may be responsible for its possible anti-fatigue properties in MS. 
Despite multiple randomized controlled trials of amantadine for MS fatigue, (Geisler et al., 1996; 
Krupp et al., 1995; Ledinek et al., 2013; Rosenberg and Appenzeller, 1988; Stein et al., 1995; 
Tomassini et al., 2004) methodological issues and conflicting results have prevented any final 
conclusion on effectiveness. A Cochrane systematic review concluded that the efficacy of 
amantadine in treating MS fatigue is poorly documented and emphasized the need for good 
quality randomized controlled trials. (Pucci et al., 2007) The most commonly reported adverse 
effects in reviewed trials were mild nausea and dizziness that did not require treatment. (Ledinek 
et al., 2013; Pucci et al., 2007; Shaygannejad et al., 2012) Considering its relative safety, wide 
availability and conflicting evidence for efficacy, we chose amantadine as a comparator in this 
study.  
5.1.2. Modafinil: Modafinil is a non-amphetamine wake-promoting agent that is FDA-approved 
for treatment of narcolepsy, obstructive sleep apnea and shift work sleep disorder. (Lange et al., 
2009) Its mechanism of action is not clear; however, it is believed to have dual noradrenergic and 
dopaminergic properties and increase cortical activity in the frontal lobes. (Kumar, 2008) 
Modafinil is the most frequently prescribed fatigue medication, as reported by patients 
participating in a global registry of for MS research, treatment, and patient education 
(NARCOMS). (Hadjimichael et al., 2008) Three randomized controlled trials produced 
inconsistent results regarding the beneficial effects of modafinil in MS fatigue. While two 
randomized trials reported no effects, (Ledinek et al., 2013; Stankoff et al., 2005) another trial 
reported clear benefits. (Lange et al., 2009) A systematic review of the effect of modafinil in 
treatment of fatigue in MS and several other neurological disorders concluded that clinical trials 
have provided inconsistent results. (Sheng et al., 2013) the most common treatment-related 
adverse effects included headache, nervousness and nausea. (Mitler et al., 2000) Because 
modafinil is widely used in clinical practice to treat MS-related fatigue and is safe and relatively 
well-tolerated; we chose it as a comparator in our pragmatic randomized controlled trial.  

20 
 
5.1.3. Methylphenidate: Psychostimulants have also been used for treatment of fatigue in 
different chronic conditions. Methylphenidate is an amphetamine like psychostimulant approved 
for the treatment of ADHD. It increases the level of monoamines in the synaptic cleft by 
enhancing their release and blocking their reuptake. Common adverse effects associated with 
methylphenidate include headaches, nervousness, irritability, tremor, insomnia, anorexia, 
gastrointestinal upset and heart palpitations. (Mitler et al., 1994) The risk of addiction is relatively 
low (less than 1-3%). (Bassetti and Aldrich, 1996) Methylphenidate has been tried in several 
randomized controlled trials of fatigue treatment in conditions other than MS. (Breitbart et al., 
2001; Cueva et al., 2012; Escalante et al., 2014; Kerr et al., 2012) Interestingly, the results of those 
trials have also been conflicting. Despite lack of rigorous evidence, methylphenidate is one of the 
commonly used and recommended medications for the treatment of fatigue in MS. (Krupp and 
Christodoulou, 2001)  
 The only randomized controlled trial of psychostimulants in MS fatigue was performed using 
pemoline; a medication used for treatment of attention deficit hyperactivity disorder (ADHD). 
(Weinshenker et al., 1992) This study concluded that pemoline may be an effective short-term 
treatment for MS fatigue, but is not well-tolerated by many patients. This medication is however 
currently not available in the US. The results of the trials of different doses of pemoline were also 
inconsistent. (Krupp et al., 1995; Weinshenker et al., 1992)  
Because psychostimulants are widely used for treatment of fatigue in MS and other chronic 
conditions, after consultation with several other neurologists and patients with MS, we decided 
to include an amphetamine-like stimulant as a comparator in our trial. We chose 
methylphenidate as a comparator, because it has been tried in several clinical trials of fatigue 
treatment (in conditions other than MS) and is an extensively used medication (for treatment of 
ADHD) with well-known side-effect and safety profiles and is inexpensive.  
In summary, amantadine, modafinil and methylphenidate are FDA-approved for the treatment 
of several neurological conditions and have been on the market for many years. Because they 
have been most commonly studied for MS fatigue, and their safety profile is well known, we will 
assess and compare their effectiveness in MS-related fatigue in a group of patients 
representative of the MS population in the US. Based on unclear efficacy of these medications, 
we concluded that the proposed trial should include a placebo treatment period. To compare the 
effectiveness of these medications against each other requires showing they are superior to 
placebo in the first place. In the proposed study, we will be powered to demonstrate the 
superiority of one (or more) of these medications to placebo and compare their efficacy against 
each other.   
5.2. Treatment arms 
Using a balanced Latin-square crossover design, subjects will be allocated, in a double-blind, 
randomized fashion, to one of the four treatment sequences (Figure 1): 1) amantadine, placebo, 
modafinil, methylphenidate; 2) placebo, methylphenidate, amantadine, modafinil; 3) modafinil, 

21 
 
amantadine, methylphenidate, placebo; and 4) methylphenidate, modafinil, placebo and 
amantadine (Figure 1). Each treatment period will be 6 weeks and there will be minimum of a 2-
week washout period between each treatment period. 
5.3. Treatment assignment  
Patients will be randomly assigned to one of the above mentioned treatment sequences in 
approximately a 1:1:1:1 ratio. The assigned study statistician will generate the randomization 
schedule and send this information to the dispensing pharmacy that will prepare and distribute 
the drug packages to UCSF and JHU MS centers.  
5.4. Treatment blinding 
Treatment sequence assignment will be blinded.  
Research coordinators, and research nurse will remain blinded to the treatment sequence 
assignment from the time of randomization of the first patient until database lock.  
Pharmacist at Johns Hopkins and UCSF and the study manager will not be blinded to treatment 
assignment. To help the participants and their treating physicians to choose the medication that 
was the most helpful to them during the clinical trial; the study pharmacist will unblind the 
participants after they finish all the study procedures by sending them an email. If, requested by 
a participant at the end of participation in the study and finishing all study procedures, the study 
nurse (or the site coordinator) will send the participant his/her completed questionnaires 
(including the baseline questionnaires and all the end-of-medication-period questionnaires). The 
study nurse (or the site coordinator) will remain blinded to the study medication assignment.    
5.5. Treating the patient  
 
5.5.1. Patient numbering 
Each patient will be uniquely identified in the study by a combination of her/his center number 
(1000 for UCSF and 2000 for JHU) and patient number. Upon signing the informed consent form, 
the patient is assigned a patient number by the site PI or study team member. At each site, the 
first patient screened is assigned patient number 1 (e.g. 1001 or 2001), and subsequent screened 
patients are assigned consecutive numbers. Once assigned to a patient, the patient number will 
not be reused. If the patient fails to be randomized, the reason for not being randomized will be 
entered in the screening log.  
 
5.5.2. Dispensing the study treatments 
Study medications will be distributed before each treatment period. They will be sent to 
participants’ mailing address through overnight FEDEX. Study medications will be mailed either 
before the baseline assessment (for the first treatment period) or during the washout periods 
between the treatment periods (for the second, third and fourth treatment periods). For the first 
treatment period, if the participant’s eligibility is confirmed while s/he is still at the screening 
visit, the study team can randomize the participant and dispense the first period medication to 

22 
 
the participant. Clinical research coordinator at each site will be responsible for dispensing study 
medications.  
 
5.5.3. Supply, storage and tracking of the study treatments 
Study medications will be compounded by the University of Iowa Pharmaceuticals. Study 
medications will be provided as capsules. During each study period, participants will receive a 
bottle containing orange/red colored capsules and a bottle containing blue colored capsules. This 
plan is designed to keep the titration schedule for all treatment periods the same and keep 
participants and evaluators blinded to treatment assignment.  
For amantadine treatment period, orange/red colored capsules will contain amantadine 100 mg 
and blue colored capsules will contain inert substance (placebo). 
For modafinil treatment period, orange/red colored capsules will contain modafinil 100 mg and 
bluecolored capsules will contain inert substance (placebo). 
For methylphenidate treatment period, both orange/red colored and blue colored capsules will 
contain methylphenidate 5 mg.  
For placebo treatment period, both orange/red colored and blue colored capsules will contain 
inert substance (placebo). 
The pharmacy will compound and supply study medications for the next six months of projected 
recruitment. Study medications will be bottled and labeled (according to the randomization table 
produced by the statistician) and will be shipped to each study site. Eight labeled bottles will be 
assigned to each participant (two bottles per study period, one containing orange/red colored 
capsules and one containing blue colored capsules). Study medications will be stored at each site 
according to pharmacy instructions. 
 
5.5.4. Instructions for prescribing and taking study treatments  
Study medications will be titrated according to the Figure 2.  
During all treatment periods, participants will start taking one orange/red colored capsule in the 
morning for one week. At week two, participants will take one orange/red colored capsule and 
one blue colored capsule in the morning. Beginning at week three, participants will take one 
orange/red colored capsule and one blue colored capsule in the morning and one orange/red 
colored capsule in the early afternoon. Beginning at week four, participants will take one 
orange/red colored capsule and one blue colored capsule in the morning and one orange/red 
colored capsule and one blue colored capsule in the early afternoon. Week five dosing schedule 
will be similar to week four. Beginning with week six, participants will taper the dosage and will 
take one orange/red colored capsule and one blue colored capsule in the morning.  
The above dosing schedule will be followed by participants who can tolerate the medication and 
dose titration. If the participants tolerate the study medications without developing any side 
effects, they will be allowed to titrate the medication according to the above schedule, even if 

23 
 
they do not receive such instructions from the study nurse. Those participants who develop new 
or worsening symptoms, are not allowed to titrate the medication before receiving such 
instructions from the study nurse. The study nurse will call or get in touch with each participant 
(through email or text) at least five times during each treatment period and will inquire about 
participants’ development of adverse events, tolerability of medication and if they can tolerate 
an increase in the dose. The schedule of nurse phone calls and the algorithm for dealing with 
participants’ issues regarding medication titration is depicted in Table 1 and Figure 3 (attached 
at the end of the document), respectively.  
 
Table 1.  Schedule of research nurse phone calls. Please note that the participants can be 
contacted ±3 days from the days shown in this table.  
 
 
Tuesday 
Wednesday Thursday 
Friday 
Saturday 
Sunday 
Monday 
Week 1 
Start med 
 
 
 
 
 
1st phone call 
Week 2 
 
 
 
 
 
 
2nd phone call 
Week 3 
 
 
 
 
 
 
3rd  phone call 
Week 4 
 
 
 
 
 
 
 
Week 5 
4th phone call for reminding or administering the end-of-period 
questionnaire and asking about adverse event and tolerability 
5th  phone call 
(for tapering 
the 
medication) 
Week 6 
 
 
 
 
 
 
 
 
 
5.5.5. Concomitant treatment 
Participants will be instructed to notify the study site about any new medications they take after 
the start of study medications. All medications and significant non-drug therapies (including 
physical therapies and blood transfusions) administered after the participants start study 
medications must be listed on the concomitant medications form on the CRF.  
 
5.5.6. Discontinuation of study treatments and premature patient withdrawal 
Participants may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn if they state an intention to withdraw, fail to return for visits, or become 
lost to follow-up for any other reason.  
If premature withdrawal occurs for any reason, the investigator team will make every effort to 
determine the primary reason for a participant’s premature withdrawal from the study and 
record this information. 
If a participant decides to stop the study medication or because of development of adverse 
events, is instructed by the study team to stop the study medication, the outcome measures of 
that particular period will be performed during the 5th week of that medication period (i.e. at the 
scheduled time frame). If the participant is continuing the study and is willing to start the study 

24 
 
medication of the next period, as long as they have been off the study medication for at least 
two weeks and they have answered the outcome questionnaires on week 5, the medication 
period can be started immediately. If a participant decides to drop out of the study, stop the 
study medication and start a medication outside of the study, the outcome questionnaires should 
be administered while the patient is still on the study medication or before they start a 
medication outside of the study.  
Study drugs must be discontinued for a given participant if the investigator determines that 
continuing it would result in a significant risk for that participant. The following events/conditions 
may be considered sufficient to support a decision about the study medication discontinuation 
in individual cases:  
- Serious adverse event 
- Withdrawal of consent 
- Pregnancy 
Participants who discontinue study medications should not be considered withdrawn from the 
study, unless one of the reasons listed above for study withdrawal are met.  
The date and primary reason for study drug discontinuation should be recorded.                                                            
 
5.5.7. Study completion 
The study will be considered completed for an individual participant when he/she completes all 
four treatment periods, or earlier in case of premature study discontinuation. The study as a 
whole will be considered completed when all enrolled participants have completed the study.   
 
5.5.8. Role of site personnel 
- 
Bardia Nourbakhsh, MD, MAS, Principal Investigator: Dr. Nourbakhsh is an assistant 
professor in the department of Neurology at JHU. He will oversee the overall conduct of 
the entire research project. He has been involved in designing clinical trials of 
symptomatic treatment in MS for the past few years and has completed formal education 
in epidemiology, biostatistics and trial design as part of the UCSF Masters’ in Clinical 
Research. He will work closely with Dr. Waubant, the study co‐PI and site PI at UCSF. He 
will be responsible for drafting the study protocol, recruiting participants in the study at 
JHU and reviewing their eligibility. He will perform full neurological examination (EDSS) at 
the screening visit for JHU patients. He will also supervise the JHU research nurse. He will 
lead monthly teleconferences with Hopkins and UCSF study team members. He will have 
twice a month telephone meetings with the UCSF study manager and JHU research nurse 
to review the progress of the study at all sites. He will identify issues related to 
recruitment and retention in the study to address them in a timely manner. He will 
oversee the overall quality control and safety of the study. He will be responsible for 
attending to and collaborating with the Study Advisory Committee. He and the study 
manager will prepare a quarterly report for submission to the DSMB. He will work with 

25 
 
Drs. Waubant for data collection and analysis, and preparation of reports and 
manuscripts. He will prepare the scientific reports for collaborative review, present data 
at scientific meetings and be a major contributor to writing and submitting related 
manuscripts. 
- 
Bridget Morris, RN, BSN JHU Research Nurse: 
- 
She will be responsible for weekly phone calls to all participants, recruited at either 
JHU or UCSF, inquiring if they experienced any side effects, collect side effects in source 
documents. Under the supervision of Dr. Nourbakhsh at JHU, she will ensure that 
subjects tolerate titration of study drug and will guide them on how to titrate the 
medication. She will also answer patients’ clinical questions that arise during the trial. 
She will bring up medical issues to the attention of the site PIs. She will document the 
outcomes of her phone calls (including reports of adverse effects and serious adverse 
effects and maximum tolerated dose). 
- 
She will explain the study and related processes to the subjects, and consent them 
for the study at JHU. She will be the primary subject contact for this study at JHU. She 
will also prepare IRB‐approved letters that will be sent to physicians who usually refer 
patients to the center for clinical trials and will be the first‐line of contact for these 
physicians who want to refer patients to the study. She will schedule study visits and 
return subjects phone calls. She will work with the MS clinic to identify potential 
candidates for the study. She will enroll subjects at JHU, collect data, and perform data 
entry and cleaning. She will meet twice a month with Drs. Nourbakhsh and Waubant, 
and the UCSF study manager to review study progress and potential issues. She will 
work with the pharmacy to dispense the study medications. She will reconcile 
shipments of study drug to subjects and remind subjects about completing necessary 
testing that is part of the primary and secondary outcomes. 
 
- 
Emmanuelle Waubant, MD, PhD, Co‐Principal Investigator: Dr. Waubant is a Professor of 
Neurology at UCSF. Dr. Waubant has extensive experience in the design and execution of 
clinical trials of anti‐inflammatory, neuroprotective and symptomatic treatments in the 
field of MS, including treatment of MS fatigue. Along with Dr. Nourbakhsh, she will 
oversee the conduct of the trial at UCSF and Hopkins. She will also recruit patients in the 
study, perform neurological examination (EDSS) on participants recruited at UCSF. She 
will be attending monthly teleconferences with UCSF and Hopkins study team members, 
pertaining to enrollment and retention. She will meet twice a month with the UCSF study 
manager and study coordinator to review progress with the trial and review issues and 
ways to troubleshoot these in a timely manner. She will work with Dr. Nourbakhsh for 
data collection and analysis, and preparation of reports and manuscripts. 
 
- 
Nisha Revirajan, UCSF Study Manager:  Dr. Revirajan is an experienced study coordinator 
who has been working with Drs. Nourbakhsh and Waubant over the past few years on 
several industry-sponsored and investigator-initiated trials. She will explain the study and 
related processes to the subjects, and consent them for the study at UCSF in conjunction 

26 
 
with the UCSF study coordinator. She will be the primary subject contact for this study at 
UCSF. She will also prepare IRB-approved letters that will be sent to physicians who 
usually refer patients to the center for clinical trials and will be the first-line of contact for 
these physicians who want to refer patients to the study. She will schedule study visits 
and return subjects phone calls. She will work with the MS clinic to identify potential 
candidates for the study. She will enroll subjects at UCSF, collect data, perform data entry 
and cleaning. She will meet twice monthly with Drs. Nourbakhsh (through teleconference) 
and Waubant, and the study team at UCSF and JHU to review study progress and potential 
issues. She will work with the pharmacy to dispense the study medications. She will 
reconcile shipments of study drug to subjects and remind subjects about completing 
necessary testing that is part of the primary and secondary outcomes. 
 
- 
TBN, UCSF Study Coordinator: She will explain the study and related processes to the 
subjects, and consent them for the study at UCSF. She will be scheduling and returning 
patients phone call. She will work with the MS clinic to identify potential candidates for 
the study. She will enroll subjects at UCSF, collect data, perform data entry, provide data 
cleaning for clinical and demographic data. She will provide time for data entry as 
necessary and will participate in teleconferences. She will work with the pharmacy to 
dispense the study medications. 
 
- 
Charles McCulloch, PhD, Statistician: He will be responsible for drafting of statistical 
methodology of the study protocol and overseeing the preparation of the randomization 
protocol in the first year and working with the pharmacist at both sites for the execution 
of randomization protocol. He will work with Drs. Nourbakhsh and Waubant to finalize 
the plan of data analysis and help with the preparation of DSMB reports. He will oversee 
the final analysis of the data at the end of the trial and report. Working with the junior 
statistician, he will prepare a complete and clean dataset for sharing upon request, and 
will participate to the preparation of manuscripts related to the study. 
- 
TBN, Junior Statistician at UCSF: S/he will work with the senior statistician to write the 
analysis plan. S/he will be responsible for setting up the RedCap database, preparation of 
case report forms, database troubleshooting, monitoring data accrual, auditing missing 
data, and monitoring recruitment. S/he will participate in generating DSMB reports by 
auditing the database, locking the database and performing analyses (if required by the 
protocol). When the data collection is complete, s/he will be responsible for database 
cleaning and locking, performing the analyses and preparing results (supervised by the 
senior statistician). 
Recruitment, visit schedule and assessments (Table 2) 
Recruitment: Eligible subjects with MS will be recruited from the Johns Hopkins MS Center, at 
which over 3,000 MS patients, who come from diverse racial/ethnic and socioeconomic 

27 
 
backgrounds and from a wide catchment area, are seen annually. We will also screen 
potentially eligible subjects using an IRB-approved Telephone Screening Script. This will allow us 
to screen patients who may or may not meet the study’s eligibility criteria. If a patient meets 
the eligibility criteria via telephone screening, we will schedule the patient to come in for a 
baseline visit. The study coordinator will call only patients of physicians on the study team. 
Screening visit: This will be the only in-person study visit. Because an MFIS score lower than the 
threshold specified in the inclusion criteria is one of the most common reasons for screening 
failure, we will use an oral consent process to administer the MFIS test. If the patient’s MFIS score 
is in the acceptable range, PI or designee will explain the study consent to study participants, and 
the rest of the study visit assessments will occur after the study participants sign the consent 
form. Screening visit procedures include review of eligibility criteria, physical exam, EDSS, 
collecting vitals, and labs, and completion of MFIS, Neuro-QoL fatigue item bank and screening 
for depression by completing HADS-depression subscale. If physical examination and/or EDSS is 
performed by one of the neurologists in the participating centers (JHU or UCSF) during a clinical 
encounter in three months prior to the screening visit and the results were available for review 
at the time of screening, there is no need to repeat them and we will use those data during the 
screening. The screening labs will be collected if the screening visit MFIS score is >33. If the 
required labs were done in 30 days prior to screening and the results were available for review 
at the time of screening, there is no need to repeat the labs (except the urine pregnancy test). 
Study participants will be enrolled into the study after the study physician confirms participants’ 
eligibility to move forward with the study. We will notify the study participants about their 
eligibility before planning the baseline fatigue assessment. Participants will be randomized to one 
of the 4 study sequences (Figure 1) within 60 days from the screening visit. 
After randomization: The study drug of the first assigned period will be mailed to the participant. 
Alternatively, if a participant’s eligibility is confirmed while s/he is still at the screening visit, the 
study team can randomize the patient and dispense the first period medication to the participant 
The baseline values of the primary and secondary endpoints of the study will be obtained through 
remote answering (web based, phone or mailed paper forms) within three days before starting 
medications. Participants will start taking the study medication of the first period of their 
assigned sequence within 60 days after the screening visit.    
Table 2 – The schedule for study procedures and assessments  
Tests and 
assessments 
Screening 
visit 
Baseline 
Weeks 
1-4 
Week  
5 
Weeks 
9-12 
Week  
13  
Weeks 
17-20 
Week  
21 
Weeks 
25-28  
Week 
 29 
Informed Consent  
X 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion 
criteria  
X 
 
 
 
 
 
 
 
 
 

28 
 
Medical history 
X 
 
 
 
 
 
 
 
 
 
Vital signs 
X 
 
 
 
 
 
 
 
 
 
Physical 
examination 
X 
 
 
 
 
 
 
 
 
 
Blood draw (safety 
labs) 
X 
 
 
 
 
 
 
 
 
 
Study drug 
dispensation  
 
X 
 
 
 
 
 
 
 
 
Study medication 
titration 
 
 
X 
 
X 
 
X 
 
X 
 
EDSS 
X 
 
 
 
 
 
 
 
 
 
MFIS 
X  
(in-person) 
X  
(web) 
 
X  
(web) 
 
X  
(web) 
 
X  
(web) 
 
X  
(web) 
HADS Depression 
subscale 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuro-QoL fatigue 
item 
X 
X 
 
X 
 
X 
 
X 
 
X 
Epworth Sleepiness 
Scale (ESS)  
X 
X 
 
X 
 
X 
 
X 
 
X 
Going forward, 
would you choose 
this medication as 
your fatigue 
treatment?  
 
 
 
X 
 
X 
 
X 
 
X 
Side effects 
assessment  
 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
6.1. Information to be collected on screening failures 
Patients who have signed the informed consent form, but fail to meet eligibility criteria for 
enrollment, will be deemed screen failures and the reason for failure will be documented on the 
screening log. Only demographic data, screening MFIS and the reason for screen failure will be 
collected.  

29 
 
6.2. Patient demographics and other baseline characteristics 
Patient demographic characteristic data include date of birth, age, sex, race, ethnicity and 
employment status. Relevant medical history will include data until the start of the study drugs 
and will capture pre-existing medical conditions and any concomitant medications taken to treat 
these conditions. Where possible, diagnoses, and not symptoms will be recorded. MS history, 
history of fatigue and previous MS and fatigue treatment will also be collected.  
6.3. Efficacy  
6.3.1. MFIS 
The MFIS is a patient-reported outcome that has been proposed by the MS Council for Clinical 
Practice Guidelines as the instrument of choice for assessing fatigue in MS (PC-3). It has been 
developed by the National MS Society (NMSS). It is derived from the 40-item Fatigue Impact Scale 
(FIS) and is a component of the MS quality of life inventory (MSQLI). It has 21 items and assesses 
more dimensions of fatigue than the other fatigue measures: physical (9 items), cognitive (10 
items) and psychosocial (2 items). The scale score is the sum of the 21 items and higher score 
indicates more severe fatigue. The maximum score is 84. The scale has shown good 
reproducibility, ease of use and good correlation with the Fatigue Severity Scale (FSS) scores. 
(Téllez et al., 2005) The MFIS also probably measures cognitive and psychosocial aspects of 
fatigue better than the FSS. A cut-off value of 38 distinguishes fatigued from non-fatigued MS 
patients. (Flachenecker et al., 2002) The NMSS has recognized MFIS as a valid and reliable 
measure of the impact of fatigue on activities of daily living in patients with MS. (Téllez et al., 
2005) A Spanish version of the MFIS has been developed and no cultural or linguistic differences 
were found in the psychometric properties of the Spanish version in patients with MS. (Kos et al., 
2005) The MFIS has been used as an endpoint in multiple clinical trials. (Gillson et al., 2002; 
Rammohan et al., 2002; Schwid et al., 2003; Stankoff et al., 2005) The MFIS can be easily 
administered in-person, over the web and on the phone and requires minimal or no guidance. 
Answering the questionnaire is possible in less than 5 minutes.  
6.3.2. Neuro-QOL fatigue item bank 
Neuro-QoL: Quality of Life in Neurological Disorders (Neuro-QOL) project was commissioned by 
the National Institute of Neurological Disorders and Stroke and has developed psychometrically 
robust and clinically relevant health-related quality of life measures applicable across 
neurological conditions. (Cella et al., 2012; Gershon et al., 2012)  The psychometric properties of 
Neuro-QoL have been assessed in MS. (Cook et al., 2015; Miller et al., 2015) The Neuro-QoL 
fatigue item bank is comprised of up to 19 items with a maximum total score of 95. Higher scores 
indicate more severe fatigue impact. This patient-reported outcome can be answered in-person, 
over the web or on the phone in less than 5 minutes.  

30 
 
6.3.3. Epworth Sleepiness Scale (ESS) 
ESS is a frequently used measure of patient-reported sleepiness in clinical neurology and sleep 
medicine. Sleepiness might be mistakenly considered synonymous with fatigue, however, there 
is complex relationship between these two conditions. Sleep problems might contribute to both 
daytime sleepiness and fatigue. Some of the prescribed medications for the treatment of fatigue 
(including modafinil and methylphenidate) have confirmed efficacy and FDA-approval for 
treatment of sleep disorders. Using ESS, we can analyze the differential effect of the study 
mediations on fatigue and sleepiness.  
ESS is a list of eight situations in which participants rate their tendency to fall asleep on a scale of 
zero to three. The total score is based on a scale of zero to 24.   
6.3.4. Single question regarding treatment satisfaction 
We will ask the participants at the end of each treatment period a question regarding their 
satisfaction with the treatment: 
“Taken into consideration the possible benefits and/or disadvantages of this medication, would 
you choose it, going forward to treat your MS fatigue?” 
Participants will answer to this question yes or no.  
6.4. Safety and tolerability 
The safety outcome will be analyzed by including all subjects who have received at least one dose 
of study medication. Participants will be analyzed according to the actual treatment received. 
The assessment of safety will be based on the frequency of adverse events. Tolerability of 
medications will be reported as the range, median and average highest tolerated dose for each 
medication.   
7. Safety monitoring 
The study medications have known safety profiles and are already FDA-approved and marketed 
for other indications. There is no requirement for routine blood work for these medications in 
clinical practice. Hence, in this pragmatic and real-world clinical trial, we will have no required in-
person clinical exam or laboratory testing for detection of adverse events; however, we will 
collect patient-reported adverse events.  
7.1. Adverse events 
An Adverse event (AE) is the appearance or worsening of any undesirable sign, symptom or 
medical condition occurring after the start of the study medications, even if the event is not 
considered to be related to study drug.  
The occurrence of AEs will be sought by non-directive questioning of the participant at each 
telephone encounter. All patient-reported AEs must be recorded with the following information:  

31 
 
- The severity grade (mild, moderate, severe) 
- Its relationship to the study medications (suspected/not suspected) 
- Its duration (start and end dates) 
- If it constitutes a serious adverse event (SAE) 
An SAE is defined as an event which: 
- is fatal or life-threatening 
- results in persistent or significant disability 
- constitutes a birth defect/congenital abnormality  
- requires inpatient hospitalization for at least 24 hours or prolongation of existing hospitalization 
for at least 24 hours. Pre-planned, elective hospital admissions are not considered SAEs. 
- is medically significant 
All AEs should be treated appropriately. Treatment may include one or more of the following: no 
action taken; study drug dosage adjustment; study drug permanently discontinued; concomitant 
medication given; non-drug therapy given; patient hospitalized.  
7.2. Pregnancies 
Female participants of child-bearing potential will have a urine pregnancy test at the screening 
visit and will be informed of the need for effective contraception to prevent pregnancy while 
participating in the study. Contraception must be used during the study and one month after 
stopping the last study medication.  
7.4. Data and Safety Monitoring Board (DSMB) 
The DSMB will be an external board comprised of one internist, one MS clinician, and one 
biostatistician (names to be determined). Before the start of the trial, the DSMB must review and 
approve the study protocol. Study PI, statistician and manager will prepare a report of all safety 
data before DSMB meetings. The DSMB will meet by teleconference every six months or sooner 
if severe AEs are brought to their attention by the study PI. They will make recommendations to 
ensure patients’ safety in the trial. Because of the nature of the study and the medications used, 
there is no need to set early stopping rules for futility or unequivocal evidence of efficacy or harm.  
 
8.Database management  
8.1. Data collection 
We will use REDCap (Research Electronic Data Capture) [https://projectredcap.org/], a secure 
web application to build and manage online surveys and databases, collect data, create the trial 
database and access the data for analysis. Most of the trial data (including screening and baseline 

32 
 
values of MFIS and questionnaires answered in each study period by the participants will be 
directly captured via REDCap forms. If participants cannot enter data online, they will complete 
a paper form and mail it to study coordinator who will do data entry. Alternatively, the study 
coordinator will call the subject who will answer questions on the phone, and data will be entered 
at that time by the study coordinator. Study coordinator will enter the data required by the 
protocol into the Electronic Case Report Forms (CRFs). Junior statistician will be responsible for 
setting up the RedCap database, preparation of case report forms, database troubleshooting, 
monitoring data accrual, auditing missing data, and monitoring recruitment. The site PIs will 
assure that the data entered into CRFs are complete and accurate.                                                      
8.2. Database management and quality control 
Junior statistician and study manager will review the data entered into CRFs by the study 
coordinators for completeness and accuracy and instruct them to make any required corrections 
or additions.  
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employs the Anatomical Therapeutic Chemical classification system. 
Medical history/current medical conditions and adverse events will be coded using the Medical 
dictionary for regulatory activities (MedDRA) terminology. 
The occurrence of any protocol deviations will be determined. After these actions have been 
completed and the database has been declared to be complete and accurate, it will be locked 
and made available for data analysis. 
9. Data analysis 
The statistical models specified in this section may be modified by including fewer covariates in 
the models in case the pre-specified models do not converge. 
9.1. Analysis sets  
Efficacy set: The efficacy set comprises all participants who have at least the primary outcome 
measured in one treatment period. Following the intention-to-treat (ITT) principle, participants 
will be analyzed according to the randomized sequence assignment, even if they actually received 
the medications in a different sequence. This method will also be used for the secondary efficacy 
endpoint. 
Safety Set: The safety set includes all patients who received at least one dose of study medication. 
Subjects will be analyzed according to the actual treatment received. The Safety Set will be used 
for all safety analyses. 
9.2. Patient demographics and other baseline characteristics  
Patient demographics and other baseline characteristics, will be summarized using frequency 
distributions (for categorical variables) and descriptive statistics of mean, standard deviation, 
minimum, median and maximum (for continuous variables). 

33 
 
Background information includes MS subtype, prior medication, past/current medical conditions, 
duration of the disease, baseline fatigue level and baseline EDSS. 
9.3. Analysis of the primary and secondary outcomes 
9.3.1. Primary and secondary efficacy outcomes 
Primary efficacy outcome: MFIS at the end of each treatment period.  
The MFIS is a patient-reported outcome that has been proposed by the MS Council for Clinical 
Practice Guidelines as the instrument of choice for assessing fatigue in MS. It has been developed 
by the National MS Society (NMSS). It is derived from the 40-item Fatigue Impact Scale (FIS) and 
is a component of the MS quality of life inventory (MSQLI). It has 21 items and assesses more 
dimensions of fatigue than the other fatigue measures: physical (9 items), cognitive (10 items) 
and psychosocial (2 items). The scale score is the sum of the 21 items and higher score indicates 
more severe fatigue. The maximum score is 84. The scale has shown good reproducibility, ease 
of use and good correlation with the Fatigue Severity Scale (FSS) scores. (Téllez et al., 2005) The 
MFIS also probably measures cognitive and psychosocial aspects of fatigue better than the FSS. 
A cut-off value of 38 distinguishes fatigued from non-fatigued MS patients. (Flachenecker et al., 
2002) The NMSS has recognized MFIS as a valid and reliable measure of the impact of fatigue on 
activities of daily living in patients with MS. (Téllez et al., 2005) A Spanish version of the MFIS has 
been developed and no cultural or linguistic differences were found in the psychometric 
properties of the Spanish version in patients with MS. (Kos et al., 2005) The MFIS has been used 
as an endpoint in multiple clinical trials. (Gillson et al., 2002; Rammohan et al., 2002; Schwid et 
al., 2003; Stankoff et al., 2005) The MFIS can be easily administered in-person, over the web and 
on the phone and requires minimal or no guidance. Answering the questionnaire is possible in 
less than 5 minutes. The MFIS questionnaire is attached in the appendix section. 
Secondary outcome: Neuro-QoL fatigue item bank score and ESS score at the end of each 
treatment period. 
9.3.2. Statistical model, hypothesis and method of analysis 
The null hypothesis for the primary endpoint is that the MFIS scores at the end of all medication 
periods (including placebo) are equal. We will use a linear mixed-effect regression model with 
the primary outcome of the study (MFIS score obtained while taking maximal tolerated or target 
dose in each treatment period) as the independent variable, and the study medication, treatment 
sequences, treatment periods and study sites as the fixed effects with the subjects as the random 
effect. The least-square means and associated standard errors will be calculated for each study 
medication. Fisher’s least-significant-difference method will be used to calculate multiple 
comparisons among medications. According to this method, the overall and global difference 
between study medications will be tested in the mixed-effect model. If this test is significant at 
0.05 level, we will make pairwise comparisons between study treatments using estimated 
contrast at 0.05 level. In a sensitivity analysis, we will check the presence of the first-order 

34 
 
carryover effect (by adding it to the model as a fixed effect). The secondary efficacy outcome will 
be analyzed using a similar mixed-effect model. 
9.3.3. Handling of missing values and discontinuations  
To minimize missing data, we have simplified the process of data collection. Instead of trying to 
collect as much information as possible, we have focused on the main research objective which 
is to determine if any of the study medications will improve fatigue and if this improvement in 
fatigue is associated with better quality of life. As such, only measures of fatigue and fatigue-
related quality of life are being considered as efficacy outcomes in this study. This will prevent 
imposing any unnecessary burden on study participants and allows us to dedicate more resources 
to maximize the quality of data collection. The outcomes of the study will be collected while the 
participants are at home or work place, with no need for in-person visits after the screening visit. 
The questionnaires are relatively short and can be answered quickly and easily by the subjects. 
Subjects will receive electronic reminders on the days they are supposed to report fatigue 
severity. Study personnel will be actively engaged during each treatment period with contacting 
the participants to review drug tolerability and guiding titration. This will likely improve patient 
participation and retention that in turn will decrease missing data. 
Study coordinators will contact subjects who have not reported fatigue severity or those who 
have decided to stop study medication to inquire about the reason of the missing values or 
dropout. With the participants’ consent, we will continue to collect data, even if they decide to 
stop taking the study medication. Using data from a similarly designed crossover clinical trial 
(Gilron et al., 2005), we estimated a conservative 20 % dropout between each treatment period 
and accounted for it in the sample size calculation. The proportion of patients who drop out of 
the study and the recorded reasons will be presented in the manuscript reporting the results of 
the trial. 
Our pre-specified primary analysis model, the linear mixed-effects model with maximum 
likelihood method, will allow handling of missing data in several treatment periods. 
 
We will run several pre-specified sensitivity analyses to explore the effect of missing data on the 
results of the trial. The first sensitivity analysis will assume that the missing data can be modeled 
based on observed data (i.e. data “missing at random”). We will then utilize the multiple 
imputations method for missing values. Multiple imputations using a linear mixed-effects 
regression model will be conducted 50 times with a random seed pre-specified to generate 50 
analysis datasets. The mixed-effects model used for the primary analysis will also be used to 
analyze each of the 50 data sets. Using Rubin’s rule (Rubin, 1996), we will then combine the 
estimates, standard error of the estimate and the p-values to provide the final reference results. 
In another sensitivity analysis, we will substitute the missing values with the highest fatigue score 
recorded during the trial, assuming severe fatigue is associated with missingness. 

35 
 
9.4. Safety and tolerability outcomes 
The safety outcome will be analyzed by including all subjects who have received at least one dose 
of study medication. Participants will be analyzed according to the actual treatment received. 
The assessment of safety will be based on the frequency of adverse events. Tolerability of 
medications will be reported as the range, median and average highest tolerated dose for each 
medication.   
9.5. Assessment of heterogeneity of treatment effect 
Our pragmatic trial, with broad eligibility criteria, will help generate evidence that will be 
generalizable. However, stakeholders (e.g. patients and clinicians) are also interested to know 
how well a treatment is likely to work for an individual. As such, assessing the heterogeneity of 
treatment effect is critical to understand the applicability of the results in individual patients. This 
issue is relevant for efficacy endpoints as well as safety and tolerability. We plan to assess the 
heterogeneity of treatment effect in the proposed trial and will explore the possibility of 
differences in efficacy, safety and tolerability of a specific study medication in a pre-specified 
subgroup of participants. Although our trial is powered to detect an average treatment effect, 
we will investigate effect modification by several baseline covariates as outlined below. 
 
A) Subjects with relapsing-remitting versus progressive MS: Although the exact pathological 
processes at play in progressive forms of MS are unknown, they are hypothesized to be 
different from relapsing-remitting forms and involve more extensively changes in the 
innate immune response. The most convincing evidence for this difference is the fact that 
FDA-approved disease-modifying treatments for relapsing MS do not prevent progression 
of disability in progressive MS. (Ontaneda et al., 2015) The severity of fatigue is also different 
between these two groups. A recent study reported that patients with primary or secondary 
progressive disease have two and a half time the odds of severe fatigue compared to patients 
with the relapsing-remitting type. (Weiland et al., 2015) The difference in the pathophysiology 
and fatigue severity between the 2 forms of MS raises the possibility of a differential response to 
drugs targeting fatigue.  
 
B) Subjects with versus without depression: Fatigue and depression are both common 
symptoms associated with MS. They are also very highly associated with each other. In 
one report, patients with clinically significant fatigue were 9 times more likely to screen 
positive for depression. Of those who screened positive for depression, 92.9% had 
clinically significant fatigue. (Taylor et al., 2014) Although the causal relationship of this 
association is not clear, it is conceivable that the response to fatigue treatment might be different 
between subjects with and without depression. However, because most fatigued subjects will 
have depression, there may be very few in the trial without depression. This issue may affect the 
assessment of effect modification by depression. 
To screen for depression, we will use Hospital Anxiety and Depression Scale (HADS), depression 

36 
 
subscale. This is a validated measure of depression in patients with MS and cutoff score of 11 has 
high sensitivity and specificity to detect depression. (Watson et al., 2014) 
 
C) Subjects on disease-modifying treatments versus those who are not: Disease-modifying 
treatments reduce inflammatory disease activity (i.e. relapse rate and MRI changes) in 
patients with relapsing MS; however, their effect on fatigue is not clear and remains a 
controversial issue.(Metz et al., 2004; Putzki et al., 2008, 2009; Wilken et al., 2013) It is a 
fair plan to explore the differential effects of anti-fatigue medications in those who do 
and those who do not receive disease-modifying treatments.  
 
D) Subjects with mild degrees of disability (EDSS<3.0) versus more severe disability 
(EDSS>=3.0): The association of fatigue and neurological disability also remains 
controversial.(Koch et al., 2009; Pittion-Vouyovitch et al., 2006) In our cohort of patients 
with early relapsing disease, we found a strong cross-sectional and longitudinal 
association between severity of fatigue (as measured by MFIS) and neurological disability 
(as measured by EDSS and MSFC). On longitudinal evaluation, each 0.5-point increase in 
EDSS was associated with 3.4-point increase in MFIS 95% CI:1.4 – 5.5, p=0.001) and each 
0.1 decrease in MSFC was associated with 0.5-point increase in MFIS (95%CI:0.1 – 0.9, 
p=0.009).   (unpublished data, manuscript in preparation). Based on our strong 
preliminary data, we hypothesize that the effect of fatigue treatment may be different 
across different levels of disability which we will explore in heterogeneity of treatment 
effect analyses.  
Expanded Disability Status Scale (EDSS) is the most commonly used scale for assessing the 
level of disability in patients with MS.(Kurtzke, 1983) It provides a total score that ranges 
from 0 to 10. Higher scores indicate more severe disability.  
 
To evaluate the heterogeneity of treatment effect, we will test the multiplicative interaction 
between treatment effect and each of the above-mentioned subgroup variables. If the statistical 
test for multiplicative interaction is significant at 0.15 level, we will further explore treatment 
effect in particular subgroups by stratification.  
 
We will report all pre-planned subgroup analyses, including the previously mentioned four 
interaction tests and stratified analyses. 
9.6. Sample size calculation 
Although statements such as “clinically meaningful” or “clinically relevant” changes in MFIS score 
have been used in a number of studies, no data have been published regarding what MFIS 
changes reflect objectively.(Larson, 2013) In a study reported by Kos et al., a 10 point or more 
change in MFIS score was considered to be clinically relevant.(Kos et al., 2007)  In our prior trial 

37 
 
of modafinil in MS fatigue(Stankoff et al., 2005), the mean change in each treatment group during 
the study was almost 10 points, which likely reflects the variability of the measure, and the fact 
that a lesser change is likely not meaningful. In our cohort of 43 patients with very early MS in a 
neuroprotection trial (Waubant et al., 2014), frequent measurements of MFIS were obtained for 
up to 3 years: we found a between-subject variance of 330 and within-subject variance of 80 with 
an intra-class correlation (ICC) of 0.80 (95% confidence interval of 0.70 to 0.88) (unpublished 
results). Using more conservative ICC of 0.7, power of 90% and type one error of 0.05 (Bonferroni 
corrected for 6 pairwise comparisons), we will need 91 patients to detect at least a 10-point 
difference in MFIS between the placebo and medication groups. Assuming 20% dropout within 
each treatment period, the total sample size for the proposed trial will be 136 subjects. 
9.7. Interim analyses 
We do not expect any of the study medications to have dramatic anti-fatigue effects and 
outperform other medications, to a point that interim analyses of efficacy would necessitate 
premature stopping of the trial. Hence, we will not perform interim analyses of efficacy in this 
study.  
10. Ethical considerations 
10.1. Regulatory and ethical compliance 
The Investigators will ensure that this study is conducted in full conformance with the principles 
of the “Declaration of Helsinki” which affords the greater protection to the individual. It is the 
mission of the physician to safeguard the health of the people. The study physicians’ knowledge 
and conscience are dedicated to the fulfilment of this mission. The clinical trial will fully adhere 
to the principles outlined in “Guideline for Good Clinical Practice” ICH Tripartite Guidelines for 
greater protection to the subject. 
The study will be submitted to site IRB for approval prior to enrolling study participants into the 
study. The IRB will be notified annually about study progress, and all important updates on the 
study or medically important events associated with the study will be submitted to IRB as the 
study progresses. 
The investigator will establish secure safeguards of confidentiality of research data as described 
in the current revision of the International Ethical Guidelines for Biomedical Research involving 
Human Subjects. The Health Insurance Portability and Accountability Act (HIPAA), also known as 
“The Privacy Rule”, has set new standards and regulations to protect patients from inappropriate 
disclosures of their “protected health information” (PHI) that could cause harm to their 
insurability, employability and/or their privacy. PHI pertains to any information that can be used 
to identify an individual which is created, used, or disclosed in the course of providing a health 
care service, such as diagnosis or treatment. HIPAA does allow for researchers to access and use 
PHI when necessary to conduct research. The Committee for Human Research will act as the 
HIPAA-required Privacy Board to review the use/disclosure of PHI for research. The study records 

38 
 
will be identified using subject’s study number, and initials to protect the privacy of the study 
participants. The study team will follow the JHU and UCSF IRB recommendations to protect the 
privacy of study participants. Study consent will also include the privacy language mandated by 
the Institution’s IRB. Vulnerable populations (including fetuses, neonates, pregnant women, 
children and prisoners) will not be involved in this study. All members of the research teams at 
JHU and UCSF have received required training in protection of human subjects in research and 
will receive refresher courses at intervals based on state and federal policies.   
10.2. Informed consent procedures 
The study investigators, or a person designated by the investigators will explain the IRB approved 
study consent to study participants and obtain signed informed consent from each subject. The 
study participants will be given ample time to review the consent, and are encouraged to ask 
questions during the consent process. For subjects not qualified or incapable of giving legal 
consent, written consent must be obtained from the legally acceptable representative. In the 
case where both the subject and his/her legally acceptable representative are unable to read; an 
impartial witness should be present during the entire informed consent discussion. After the 
subject and representative, have orally consented to participation in the trial, the witness’ 
signature on the form will attest that the information in the consent form was accurately 
explained and understood. The study participants are encouraged to ask questions about the 
study during the study participation period. The UCSF study participants will be provided with 
the California Experimental Subject’s Bill of Rights. The investigator or designee must also explain 
to the subjects that they are completely free to refuse to enter the study or to withdraw from it 
at any time, for any reason. The study participants will be notified about the new study 
information during the study participation period, and will be re-consented when applicable. A 
copy of the signed informed consent form will be given to the subjects for their records. 
10.4. Publication of the study protocol and results 
The key design elements of this protocol will be posted in a publicly accessible database such 
as clinicaltrials.gov. Upon request from clinical or research community, a complete, de-identified 
copy of the final dataset used for the final analyses will be made available within one year after 
the completion and publication of the study results. The dataset will be sent electronically 
through secure portals. In addition, we will also explore how data could be made available to 
investigators around the world through other channels such as the NIH or the National MS 
Society or other types of websites allowing data sharing.  
11. Protocol adherence 
Investigators ascertain they will apply due diligence to avoid protocol deviations. Any change or 
addition to the protocol can only be made in a written protocol amendment. Only amendments 
that are required for patient safety may be implemented prior to IRB approval. 

39 
 
12. References  
Auret, K.A., Schug, S.A., Bremner, A.P., and Bulsara, M. (2009). A randomized, double-blind, 
placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with 
advanced cancer. J. Pain Symptom Manage. 37, 613–621. 
Bassetti, C., and Aldrich, M.S. (1996). Narcolepsy. Neurol. Clin. 14, 545–571. 
Blaney, D.B.E., and Lowe-Strong, A. (2009). The impact of fatigue on communication in multiple 
sclerosis. The insider’s perspective. Disabil. Rehabil. 31, 170–180. 
Braley, T.J., and Chervin, R.D. (2010). Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and 
Treatment. Sleep 33, 1061–1067. 
Breitbart, W., Rosenfeld, B., Kaim, M., and Funesti-Esch, J. (2001). A randomized, double-blind, 
placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients 
with human immunodeficiency virus disease. Arch. Intern. Med. 161, 411–420. 
Cella, D., Lai, J.-S., Nowinski, C.J., Victorson, D., Peterman, A., Miller, D., Bethoux, F., 
Heinemann, A., Rubin, S., Cavazos, J.E., et al. (2012). Neuro-QOL: brief measures of health-
related quality of life for clinical research in neurology. Neurology 78, 1860–1867. 
Cook, K.F., Victorson, D.E., Cella, D., Schalet, B.D., and Miller, D. (2015). Creating meaningful 
cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance 
using standard setting with patients and providers. Qual. Life Res. Int. J. Qual. Life Asp. Treat. 
Care Rehabil. 24, 575–589. 
Cueva, J.F., Calvo, M., Anido, U., León, L., Gallardo, E., Areses, C., Bernárdez, B., Gayoso, L., 
García, J., Jesús Lamas, M., et al. (2012). Methylphenidate in the management of asthenia in 
breast cancer patients treated with docetaxel: results of a pilot study. Invest. New Drugs 30, 
688–694. 
Escalante, C.P., Meyers, C., Reuben, J.M., Wang, X., Qiao, W., Manzullo, E., Alvarez, R.H., 
Morrow, P.K., Gonzalez-Angulo, A.M., Wang, X.S., et al. (2014). A randomized, double-blind, 2-
period, placebo-controlled crossover trial of a sustained-release methylphenidate in the 
treatment of fatigue in cancer patients. Cancer J. Sudbury Mass 20, 8–14. 
Feys, P., Gijbels, D., Romberg, A., Santoyo, C., Gebara, B., de Noordhout, B.M., Knuts, K., 
Béthoux, F., de Groot, V., Vaney, C., et al. (2012). Effect of time of day on walking capacity and 
self-reported fatigue in persons with multiple sclerosis: a multi-center trial. Mult. Scler. 
Houndmills Basingstoke Engl. 18, 351–357. 
Flachenecker, P., Kümpfel, T., Kallmann, B., Gottschalk, M., Grauer, O., Rieckmann, P., 
Trenkwalder, C., and Toyka, K.V. (2002). Fatigue in multiple sclerosis: a comparison of different 
rating scales and correlation to clinical parameters. Mult. Scler. Houndmills Basingstoke Engl. 8, 
523–526. 

40 
 
Foley, J.F., and Brandes, D.W. (2009). Redefining functionality and treatment efficacy in 
multiple sclerosis. Neurology 72, S1–S11. 
Frohman, E.M., Racke, M.K., and Raine, C.S. (2006). Multiple sclerosis--the plaque and its 
pathogenesis. N. Engl. J. Med. 354, 942–955. 
Geisler, M.W., Sliwinski, M., Coyle, P.K., Masur, D.M., Doscher, C., and Krupp, L.B. (1996). The 
effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch. Neurol. 
53, 185–188. 
Gershon, R.C., Lai, J.S., Bode, R., Choi, S., Moy, C., Bleck, T., Miller, D., Peterman, A., and Cella, 
D. (2012). Neuro-QOL: quality of life item banks for adults with neurological disorders: item 
development and calibrations based upon clinical and general population testing. Qual. Life 
Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 21, 475–486. 
Gillson, G., Richard, T.L., Smith, R.B., and Wright, J.V. (2002). A double-blind pilot study of the 
effect of Prokarin on fatigue in multiple sclerosis. Mult. Scler. Houndmills Basingstoke Engl. 8, 
30–35. 
Gilron, I., Bailey, J.M., Tu, D., Holden, R.R., Weaver, D.F., and Houlden, R.L. (2005). Morphine, 
gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352, 1324–1334. 
Hadjimichael, O., Vollmer, T., Oleen-Burkey, M., and North American Research Committee on 
Multiple Sclerosis (2008). Fatigue characteristics in multiple sclerosis: the North American 
Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual. Life Outcomes 6, 
100. 
Hayden, F.G. (1996). Combination antiviral therapy for respiratory virus infections. Antiviral Res. 
29, 45–48. 
Induruwa, I., Constantinescu, C.S., and Gran, B. (2012). Fatigue in multiple sclerosis - a brief 
review. J. Neurol. Sci. 323, 9–15. 
Janardhan, V., and Bakshi, R. (2002). Quality of life in patients with multiple sclerosis: the 
impact of fatigue and depression. J. Neurol. Sci. 205, 51–58. 
Kerr, C.W., Drake, J., Milch, R.A., Brazeau, D.A., Skretny, J.A., Brazeau, G.A., and Donnelly, J.P. 
(2012). Effects of methylphenidate on fatigue and depression: a randomized, double-blind, 
placebo-controlled trial. J. Pain Symptom Manage. 43, 68–77. 
Koch, M., Mostert, J., Heerings, M., Uyttenboogaart, M., and De Keyser, J. (2009). Fatigue, 
depression and disability accumulation in multiple sclerosis: a cross-sectional study. Eur. J. 
Neurol. 16, 348–352. 

41 
 
Kos, D., Kerckhofs, E., Carrea, I., Verza, R., Ramos, M., and Jansa, J. (2005). Evaluation of the 
Modified Fatigue Impact Scale in four different European countries. Mult. Scler. Houndmills 
Basingstoke Engl. 11, 76–80. 
Kos, D., Duportail, M., D’hooghe, M., Nagels, G., and Kerckhofs, E. (2007). Multidisciplinary 
fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult. Scler. 
Houndmills Basingstoke Engl. 13, 996–1003. 
Krupp, L. (2006). Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly 
reported symptom of the disease. Mult. Scler. Houndmills Basingstoke Engl. 12, 367–368. 
Krupp, L.B., and Christodoulou, C. (2001). Fatigue in multiple sclerosis. Curr. Neurol. Neurosci. 
Rep. 1, 294–298. 
Krupp, L.B., Coyle, P.K., Doscher, C., Miller, A., Cross, A.H., Jandorf, L., Halper, J., Johnson, B., 
Morgante, L., and Grimson, R. (1995). Fatigue therapy in multiple sclerosis: results of a double-
blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 45, 1956–
1961. 
Kumar, R. (2008). Approved and investigational uses of modafinil : an evidence-based review. 
Drugs 68, 1803–1839. 
Kurtzke, J.F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability 
status scale (EDSS). Neurology 33, 1444–1452. 
Lange, R., Volkmer, M., Heesen, C., and Liepert, J. (2009). Modafinil effects in multiple sclerosis 
patients with fatigue. J. Neurol. 256, 645–650. 
Larson, R.D. (2013). Psychometric Properties of the Modified Fatigue Impact Scale. Int. J. MS 
Care 15, 15–20. 
Ledinek, A.H., Sajko, M.C., and Rot, U. (2013). Evaluating the effects of amantadin, modafinil 
and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. 
Clin. Neurol. Neurosurg. 115 Suppl 1, S86–S89. 
Lerdal, A., Celius, E.G., Krupp, L., and Dahl, A.A. (2007). A prospective study of patterns of 
fatigue in multiple sclerosis. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 14, 1338–1343. 
Metz, L.M., Patten, S.B., Archibald, C.J., Bakker, J.I., Harris, C.J., Patry, D.G., Bell, R.B., Yeung, M., 
Murphy, W.F., Stoian, C.A., et al. (2004). The effect of immunomodulatory treatment on 
multiple sclerosis fatigue. J. Neurol. Neurosurg. Psychiatry 75, 1045–1047. 
Miller, D.M., Bethoux, F., Victorson, D., Nowinski, C.J., Buono, S., Lai, J.-S., Wortman, K., Burns, 
J.L., Moy, C., and Cella, D. (2015). Validating Neuro-QoL short forms and targeted scales with 
people who have multiple sclerosis. Mult. Scler. Houndmills Basingstoke Engl. 

42 
 
Mitler, M.M., Aldrich, M.S., Koob, G.F., and Zarcone, V.P. (1994). Narcolepsy and its treatment 
with stimulants. ASDA standards of practice. Sleep 17, 352–371. 
Mitler,  null, Harsh,  null, Hirshkowitz,  null, and Guilleminault,  null (2000). Long-term efficacy 
and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness 
associated with narcolepsy. Sleep Med. 1, 231–243. 
Morrow, S.A., Smerbeck, A., Patrick, K., Cookfair, D., Weinstock-Guttman, B., and Benedict, 
R.H.B. (2013). Lisdexamfetamine dimesylate improves processing speed and memory in 
cognitively impaired MS patients: a phase II study. J. Neurol. 260, 489–497. 
Ontaneda, D., Fox, R.J., and Chataway, J. (2015). Clinical trials in progressive multiple sclerosis: 
lessons learned and future perspectives. Lancet Neurol. 14, 208–223. 
Pittion-Vouyovitch, S., Debouverie, M., Guillemin, F., Vandenberghe, N., Anxionnat, R., and 
Vespignani, H. (2006). Fatigue in multiple sclerosis is related to disability, depression and quality 
of life. J. Neurol. Sci. 243, 39–45. 
Pucci, E., Branãs, P., D’Amico, R., Giuliani, G., Solari, A., and Taus, C. (2007). Amantadine for 
fatigue in multiple sclerosis. Cochrane Database Syst. Rev. CD002818. 
Putzki, N., Katsarava, Z., Vago, S., Diener, H.C., and Limmroth, V. (2008). Prevalence and severity 
of multiple-sclerosis-associated fatigue in treated and untreated patients. Eur. Neurol. 59, 136–
142. 
Putzki, N., Yaldizli, O., Tettenborn, B., and Diener, H.C. (2009). Multiple sclerosis associated 
fatigue during natalizumab treatment. J. Neurol. Sci. 285, 109–113. 
Rammohan, K.W., Rosenberg, J.H., Lynn, D.J., Blumenfeld, A.M., Pollak, C.P., and Nagaraja, H.N. 
(2002). Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple 
sclerosis: a two centre phase 2 study. J. Neurol. Neurosurg. Psychiatry 72, 179–183. 
Rosenberg, G.A., and Appenzeller, O. (1988). Amantadine, fatigue, and multiple sclerosis. Arch. 
Neurol. 45, 1104–1106. 
Rubin, D.B. (1996). Multiple Imputation after 18+ Years. J. Am. Stat. Assoc. 91, 473–489. 
Schwid, S.R., Petrie, M.D., Murray, R., Leitch, J., Bowen, J., Alquist, A., Pelligrino, R., Roberts, A., 
Harper-Bennie, J., Milan, M.D., et al. (2003). A randomized controlled study of the acute and 
chronic effects of cooling therapy for MS. Neurology 60, 1955–1960. 
Shaygannejad, V., Janghorbani, M., Ashtari, F., and Zakeri, H. (2012). Comparison of the effect 
of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, 
blinded, crossover study. Neurol. Res. 34, 854–858. 

43 
 
Sheng, P., Hou, L., Wang, X., Wang, X., Huang, C., Yu, M., Han, X., and Dong, Y. (2013). Efficacy 
of modafinil on fatigue and excessive daytime sleepiness associated with neurological 
disorders: a systematic review and meta-analysis. PloS One 8, e81802. 
Smith, M.M., and Arnett, P.A. (2005). Factors related to employment status changes in 
individuals with multiple sclerosis. Mult. Scler. Houndmills Basingstoke Engl. 11, 602–609. 
Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L., Moreau, T., 
Pelletier, J., Lubetzki, C., Clanet, M., et al. (2005). Modafinil for fatigue in MS: a randomized 
placebo-controlled double-blind study. Neurology 64, 1139–1143. 
Stein, D.P., Dambrosia, J.M., and Dalakas, M.C. (1995). A double-blind, placebo-controlled trial 
of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann. N. Y. 
Acad. Sci. 753, 296–302. 
Taylor, K.L., Hadgkiss, E.J., Jelinek, G.A., Weiland, T.J., Pereira, N.G., Marck, C.H., and van der 
Meer, D.M. (2014). Lifestyle factors, demographics and medications associated with depression 
risk in an international sample of people with multiple sclerosis. BMC Psychiatry 14, 327. 
Tejani, A.M., Wasdell, M., Spiwak, R., Rowell, G., and Nathwani, S. (2012). Carnitine for fatigue 
in multiple sclerosis. Cochrane Database Syst. Rev. 5, CD007280. 
Téllez, N., Río, J., Tintoré, M., Nos, C., Galán, I., and Montalban, X. (2005). Does the Modified 
Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult. Scler. 
Houndmills Basingstoke Engl. 11, 198–202. 
Tomassini, V., Pozzilli, C., Onesti, E., Pasqualetti, P., Marinelli, F., Pisani, A., and Fieschi, C. 
(2004). Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of 
fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J. 
Neurol. Sci. 218, 103–108. 
Toosy, A., Ciccarelli, O., and Thompson, A. (2014). Symptomatic treatment and management of 
multiple sclerosis. Handb. Clin. Neurol. 122, 513–562. 
Wagner, G.J., and Rabkin, R. (2000). Effects of dextroamphetamine on depression and fatigue in 
men with HIV: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 61, 436–440. 
Watson, T.M., Ford, E., Worthington, E., and Lincoln, N.B. (2014). Validation of Mood Measures 
for People with Multiple Sclerosis. Int. J. MS Care 16, 105–109. 
Waubant, E., Maghzi, A.-H., Revirajan, N., Spain, R., Julian, L., Mowry, E.M., Marcus, J., Liu, S., 
Jin, C., Green, A., et al. (2014). A randomized controlled phase II trial of riluzole in early multiple 
sclerosis. Ann. Clin. Transl. Neurol. 1, 340–347. 
Weiland, T.J., Jelinek, G.A., Marck, C.H., Hadgkiss, E.J., van der Meer, D.M., Pereira, N.G., and 
Taylor, K.L. (2015). Clinically significant fatigue: prevalence and associated factors in an 

44 
 
international sample of adults with multiple sclerosis recruited via the internet. PloS One 10, 
e0115541. 
Weinshenker, B.G., Penman, M., Bass, B., Ebers, G.C., and Rice, G.P. (1992). A double-blind, 
randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 
42, 1468–1471. 
Wilken, J., Kane, R.L., Sullivan, C.L., Gudesblatt, M., Lucas, S., Fallis, R., You, X., and Foulds, P. 
(2013). Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis 
Treated with Natalizumab: The ENER-G Study. Int. J. MS Care 15, 120–128. 
Yacoubian, T.A., and Standaert, D.G. (2009). Targets for neuroprotection in Parkinson’s disease. 
Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1792, 676–687. 
 
Figure 3- Algorithm to be used by research nurse to address participants’ issues during medication 
titration.  
 
 
 
 
 
 
 
 
 

45 
 
 

46 
 
 

1 
 
Statistical analysis plan for the TRIUMPHANT-MS trial 
 
 
Design:  4 period, 4 treatment cross-over design. 
 
Data subsets to be analyzed: 
 
1. Data subset for all efficacy analyses: The efficacy dataset comprises all participants who 
have the primary outcome measured in week 5 of at least 1 treatment period. Following 
the intention-to-treat (ITT) principle, participants will be analyzed according to the 
randomized sequence assignment, even if they actually received the medications in a 
different sequence.  
2. Data subset for all safety analyses: The safety dataset includes all patients who received 
at least one dose of any study medication. Subjects will be analyzed according to the 
actual treatment received.  
 
Statistical Analysis Plans: 
 
Efficacy analyses: 
 
1. Outcomes 
a. Primary: MFIS score obtained during week 5 of each treatment period. 
b. Secondary: Secondary outcomes: Neuro-QoL fatigue item bank score and Epworth 
sleepiness scale during week 5 of each treatment period.  
c. Exploratory: Exploratory outcomes:  Subscales of the MFIS during week 5 of each 
treatment period, the proportion of patients who achieve a minimal clinically 
important reduction in the MFIS score (compared to the baseline measurement) 
defined as either a 10 or 14 point reduction (or more).  
2. Analyses 
a. We will use a linear mixed-effect regression model (SAS Proc MIXED) in the 
efficacy dataset for the primary outcome measure utilizing restricted maximum 
likelihood fitting and Kenward-Roger degree of freedom adjustments.  The fixed 
predictors will be study medication (categorical placebo, Amantadine, Modafinil, 
Methylphenidate), treatment sequence (categorical 1 to 4), treatment period 
(categorical 1 to 4), baseline outcome and study site (categorical JHU/UCSF) and 
subjects as a random effect. If the adjusted test of treatment differences is 
significant at the α=0.05 level, we will make pairwise comparisons between study 
treatments using estimated contrasts at the α=0.05 level.   
b. Least squares means, along with 95% confidence intervals will be reported for 
each drug and the placebo.   
c. The other efficacy outcomes will be analyzed using similar mixed-effect models. 
d. Diagnostic checks 

2 
 
i. Carry-over effects will be assessed by including an additional predictor of 
treatment in the previous time period (missing for time period 1) and 
testing its significance at α=0.05 
ii. Approximate normality will be assessed by calculating the conditional, 
studentized residuals and assessing: 
1. Approximate normality of a histogram.  
2. Absence of outliers (as judged by studentized residuals larger than 
3 in absolute value)  and, if present, their influence of outliers.  
3. A plot of studentized residuals versus predicted values.  
e. Heterogeneity of treatment effects 
i. For each of the following potential effect modifiers (all measured at 
baseline) an analysis will be performed to assess heterogeneity of 
treatment effects.   
1. relapsing-remitting vs progressive MS,  
2. depression (HADS>11),  
3. on disease modifying treatments (yes/no),  
4. mild vs more severe disability (EDSS<3).   
ii. The analysis will be a repetition of the primary, mixed model analysis but 
additionally including an interaction of the effect modifier and the 
treatment effects.  If the p-value for interaction is 0.15 or less, subgroup 
analyses will be conducted within each subgroup defined by the effect 
modifier.   
f. Missing data 
i. We do not expect there to be significant missing data.  Furthermore, the 
use of mixed model analyses provide protection against bias due to missing 
data.  However, if there is significant missing data for any variable (defined 
as >15%) we will conduct a sensitivity analysis using multiple imputation.  
 
 
Safety analyses: 
 
1. Outcomes 
a. Adverse events 
b. Tolerability 
i. Achieving maximum dose 
ii. Achieving half maximum dose 
iii. Discontinuing medication (maximum dose of zero) 
iv. Maximum dose achieved 
2. Analyses 
a.  Total number of adverse events reported by body system (MedDRA SOC) will be 
tabulated by drug.  
b. Number and percentage of patients with each type of event by body system 
(MedDRA SOC) will be tabulated by drug. 
c. Total number of recorded adverse events will be reported by drug. 

3 
 
d. The percentage of patients who reported at least one adverse effect will be 
reported by drug. 
e. For all tolerability measures except maximum dose, the percentage achieving the 
endpoint will be tabulated.  
f. For maximum dose achieved, the average and range will be calculated for each 
drug.  Also, 95% confidence intervals will be calculated for each drug.  This will be 
achieved by treating maximum dose as the outcome in a mixed model analysis 
(similar to the primary outcome analysis) with a single predictor of drug and with 
patient as a random effect.  Least squares means and their 95% confidence 
intervals will be calculated.